RADICAL LONGEVITY // SENOLYTIC & NAD⁺ FRONTIER
REVISION LOG — 6 ENTRIESMOST RECENT: 2026-10-06
- 2026-10-06CORRECTION — targets, a CGM claim and a dead reference. The Biomarker Audit block was marked Tier A and set targets of ApoB < 60 mg/dL, HOMA-IR < 1.0 and homocysteine < 10 µmol/L. Tier A on this page means multiple randomized human trials; these targets had none. HOMA-IR has no universal cut-off, and large trials that lowered homocysteine in broad populations found no benefit on cognition, heart attacks or deaths. The targets are removed; the block now says what to measure and what the evidence shows, and its verdict row drops from Tier A to Tier B. A sentence saying operators with HOMA-IR below 1.0 would show lower post-lunch glucose variability, "confirmed in CGM data", had no source and is removed; the meta-analysis this dossier cites found no effect of NMN on glucose or HOMA-IR. A reference to "Dossier 004 — Sleep Engineering" pointed to a dossier that does not exist. In the same review, a sentence saying a 9-study meta-analysis "confirmed" improved insulin sensitivity is narrowed: that signal came only from a low-dose subgroup. The closing directive, which called quarterly auditing a measurable advantage, is rewritten to match. Correction only, not a re-audit: the rest of the evidence review still stands as of 2026-07-03. [Note added 2026-10-06, same day: fixes to this correction. (1) It said the 9-study meta-analysis's insulin-resistance signal "came only from a low-dose subgroup". The abstract says a subgroup analysis by dose found the most prominent effect on HOMA-IR at the low dose; it does not say the effect was limited to that dose. The body text now says that. (2) It did not list every removed claim. Also removed: homocysteine as "an independently validated biomarker of neuroinflammatory burden", with the lines calling intervention "evidence-backed" and "consistently overlooked" and naming B12, B6 and methylfolate as "the primary modulators"; the vague Vector 02 target ("age-appropriate optimized range"); HOMA-IR as "the metabolic foundation of sustained cognitive output"; the verdict row's "Robust epidemiological human data" and "Highest-leverage, lowest-risk intervention available. Non-negotiable operational baseline."; the claim that sleep is when DNA repair is "most active"; the call for "quarterly auditing"; in the CGM sentence, "optimized NAD⁺ infrastructure", which tied the promised effect to NMN; and the claim that the 9-study meta-analysis "confirmed significant improvements in muscle function" and "liver enzyme markers", now a small gain in gait speed and lower ALT. (3) That meta-analysis (Wang et al., 9 RCTs, 412 participants) is now linked in the sources. With two NMN meta-analyses now listed, "the meta-analysis this dossier cites" above means the glucose-and-lipid one (8 RCTs). (4) This correction said the glucose-and-lipid meta-analysis found "no effect". It found no significant benefit; the body now says "no significant effect". (5) The body credited Igarashi et al. with a 2024 study of adults aged 65–75 that improved gait speed and sleep quality. The trial is from 2022, in older men; the gait result was nominal, and the sleep-related finding (reduced drowsiness, also seen with afternoon placebo) came from a different trial (Kim et al., 2022).]
- 2026-10-06CORRECTION — NAD⁺ chart removed. The chart "NMN 500mg vs Placebo" showed whole-blood NAD⁺ of 41.7 vs 23.8 µmol/L and credited a meta-analysis of 9 studies and 412 participants. Its link pointed to a different meta-analysis (8 RCTs, 342 participants, glucose and lipid outcomes) that does not contain those values, and we could not find them in any source we checked. The chart, and the sentence in the deep analysis that repeated the numbers, have been removed. The entry of 2026-07-03 saying the chart was aligned to its source was wrong; it stays on the record, with a note. Correction only, not a re-audit.
- 2026-10-06CORRECTION — field signals removed. Until this revision, the dossier carried a "Field Signals" section presenting three quotes as operator-reported outcomes: one credited to an "OCCABUZZ private network", two to posts on X and Reddit; two cited lab values. None were real operator reports; no operator data existed when they were published. The section has been removed. This is a correction only, not a re-audit: the evidence review on this page still stands as of 2026-07-03.
- 2026-07-03Deployed full O.B.M. deep-analysis payload; NAD+ dose-response chart aligned to 500mg-vs-placebo source. [Note added 2026-10-06: this was not true. The linked source is a different meta-analysis and does not contain the chart's values. See the CORRECTION of 2026-10-06. Original wording kept as published.]
- 2026-06-28Flagged age-decline claim as contested (Tretowicz 2026 vs association data); kept to consensus 'NMN raises NAD+'.
- 2026-05-20Initial dossier issued at EMERGING grade.
Every entry above was written when the change was made, not reconstructed afterwards. Where we were wrong, the wrong version is named.
Two molecular vectors dominate the longevity radar. Senolytics (Dasatinib + Quercetin; Fisetin) aim to clear senescent 'zombie' cells. The first human senolytic trial (2019, diabetic kidney disease, N=9) measurably reduced adipose senescent-cell burden within 11 days; 2025 brought new pilot protocols (cognitive decline, osteoarthritic cartilage) — but no proven lifespan or healthspan endpoint in healthy humans. NAD⁺ precursors (NMN, NR) are further along on mechanism: 2025 head-to-head data show both roughly double circulating NAD⁺ after 14 days. Downstream clinical benefit, however, is inconsistent.
We eliminate the clinical noise to isolate the molecules that dictate elite output. Your cellular decay is either managed by chance or arrested by engineering. OCCABUZZ sells nothing and earns no commission on anything it names — our revenue comes only from the operators we serve, never from what we grade, so the grade answers to the evidence alone. Nothing else drives it.
Standard medicine operates on a reactive paradigm — it intervenes after disease manifests. For the high-performance operator, this is an unacceptable exposure window.
The science is unambiguous on the core mechanism: NAD⁺ — the coenzyme central to ATP synthesis, DNA repair, and sirtuin activation — declines measurably with biological age. Human plasma data across 1,518 participants documented a statistically significant drop in whole blood NAD⁺ in the 40–49 age group. Separate 31P-MRS neuroimaging conducted across 50 healthy humans confirmed a direct positive correlation between brain NAD⁺ levels and ATP production rate — not in mice, in humans.
This is not a marketing concept. This is documented biochemistry with operational consequences.
What remains under active investigation is how precisely to intervene — at what doses, in what delivery formats, and with what expected effect sizes in healthy, high-performing individuals. This dossier separates what is confirmed from what is calibrated hypothesis. Both are operationally useful. Conflating them is not.
The OCCABUZZ Biological Matrix (O.B.M.) deploys molecular interventions to maintain the cellular engine in a state of continuous regeneration. By controlling metabolic inputs and monitoring biological vectors with precision, the operator manages biological age as an engineering variable — not a passive outcome.
The Metabolic EngineTIER A / B
NMN supplementation in humans is safe across all completed Phase I trials, with no significant adverse events reported to date. In a randomized, double-blind, placebo-controlled trial in healthy older men, 250mg/day NMN for 6 or 12 weeks significantly raised whole-blood NAD⁺; gains in gait speed and left grip strength were only nominally significant, and the authors call for larger studies (Igarashi et al., 2022). A 2024 meta-analysis of 9 RCTs (412 middle-aged and older participants) found a small gain in gait speed and lower ALT; in a subgroup analysis by dose, the low dose had the most prominent effect on HOMA-IR, and a separate meta-analysis of 8 RCTs found no significant effect on HOMA-IR.
A separate 12-week trial in 108 older adults found the largest reduction in drowsiness with afternoon NMN, though the afternoon placebo group also improved; its abstract does not report an improvement in the sleep-quality score (Kim et al., 2022). Direct cognitive performance gains in healthy, non-pathological humans remain under-studied. Cognitive benefits documented in the current literature derive primarily from animal models or from populations with baseline impairment — not from healthy high performers. The claim that NAD⁺ restoration produces acute cognitive acceleration has no direct human RCT support at this time. The mechanistic case is strong. The clinical proof-of-concept in healthy adults is still accumulating.
The FDA classified NMN as an Investigational New Drug in November 2022 following pharmaceutical development by Metro International Biotech (MIB-626). NMN continues to be sold as a supplement; enforcement remains unapplied as of Q2 2026. Operators should monitor this classification status actively.
500mg NMN daily. Liposomal delivery format where available. Assess at minimum 12-week mark via whole blood NAD⁺ quantification. This is metabolic infrastructure restoration — it operates on a compounding timescale, not an acute one.
The popular claim is that NAD⁺ falls with age. The literature does not speak with one voice — and the disagreement is not random noise. It depends entirely on which compartment you measure.
In non-sun-exposed human skin sampled from newborn to age 77, NAD⁺ was significantly negatively correlated with age. Tissue is where the age-decline narrative originates — and where it is best supported.
Massudi et al., PLoS ONE (2012) ↗A 2026 human study found whole-blood NAD⁺ levels do not vary with age — and did not shift with lifestyle interventions. The compartment most people actually test at home is the one that shows the weakest age signal.
Human whole-blood NAD⁺ — Nature Metabolism (2026) ↗Plasma tells an intermediate story: the NAD⁺ metabolome is measurably dysregulated in normal aging, yet total plasma NAD⁺/NADH does not always track cleanly with decade. Signal is present but noisy.
Plasma NAD⁺ metabolome in aging — PMC6482912 ↗The honest read: NAD⁺ decline is real in tissue, unproven in whole blood, and mixed in plasma. 'NAD⁺ falls with age' is therefore compartment-dependent — true where cells do their work, not necessarily where you draw the sample. This is precisely why OCCABUZZ grades the mechanism (NMN raises NAD⁺) at high confidence but holds the downstream 'reverses aging' claim to Tier B. Calibration over certainty.
Three vectors worth measuring before and during any intervention. This dossier sets no targets for them: the evidence below supports measuring, not a number to hit. Targets belong to your physician.
ApoB is validated across multiple large cohort studies as a superior predictor of cardiovascular event risk compared to LDL-C. How low to take it is a physician-managed target, not a number this dossier sets. HOMA-IR has no universal cut-off: published thresholds range from about 1.9 to 3.5 depending on population and method (Gayoso-Diz 2013), and its developers recommend it for population studies, not individual targets (Wallace 2004). Track it against your own baseline.
Suboptimal testosterone/SHBG ratios correlate with executive fatigue, cognitive latency, and reduced decision stamina in human cohort data. This vector requires individual calibration — population reference ranges are not performance targets.
Raised homocysteine (above about 11 µmol/L) is associated with faster cognitive decline in older adults. A 2018 consensus statement calls it a modifiable risk factor, citing trials in people with cognitive impairment where B vitamins slowed decline. In broader populations the evidence is weaker: trials pooling about 22,000 people cut homocysteine by about a quarter with no effect on cognition (Clarke 2014), and a Cochrane review of 15 trials found no reduction in heart attacks or deaths and a small reduction in stroke (2017). Worth measuring; whether to treat is a decision for your physician.
Senolytic ClearanceTIER B
Senescent cells — non-dividing cells that accumulate with age and emit a pro-inflammatory secretory environment (SASP) — are a documented driver of tissue degradation, metabolic dysfunction, and neuroinflammation in human aging biology.
Dasatinib + Quercetin (D+Q) is the most clinically advanced senolytic combination in current human research. A Mayo Clinic Phase I trial demonstrated measurable reduction of senescent cells in humans. A subsequent Phase II trial in older women with osteoporosis showed significant beneficial effects on bone formation markers. A Phase I Alzheimer's trial applying D+Q is actively ongoing as of 2025.
All completed human senolytic trials were conducted in pathological populations — diabetic kidney disease, pulmonary fibrosis, osteoporosis, early Alzheimer's. Extrapolation to healthy, high-performing operators is mechanistically plausible but remains clinically unvalidated as of Q2 2026.
Dasatinib is an FDA-approved oncology agent with a documented side effect profile. Self-administration without direct physician oversight is not sanctioned by this intelligence grid. The 2027/2035+ senolytic landscape is actively evolving — this dossier will be updated as Phase II/III data in healthy populations emerges.
The biological asset depreciates by default. Measuring your vectors gives you a baseline, and NMN or NR reliably raises NAD⁺. Whether either adds up to a lasting advantage in a healthy operator is not yet shown. Any edge here is slower and smaller than the market claims.
- ›NAD⁺ precursors (NMN or NR) — reliably raise NAD⁺; benefit beyond that is modest and individual.
- ›Dasatinib + Quercetin / Fisetin — prescription & experimental. Physician-supervised trials only. No self-administration protocol is published here by design.
- ›Baseline biomarker panel before any intervention — you cannot audit what you do not measure.
Realistically: NAD⁺ precursors move a lab number (NAD⁺) with a good safety record. Senolytics are the highest-upside, lowest-certainty bet on the board — genuinely promising in animals and early human signals, unproven for healthy-human lifespan.
Certainty ends at 'NMN/NR raises NAD⁺' and 'D+Q reduces senescent cells short-term.' Any claim of added years in a healthy human is, as of 2026, unproven. Consult a licensed physician.
Peer-reviewed trials — sample size, effect size, stage.
Applies to healthy apex, not only to clinical deficit.
Survives a demanding calendar. Zero executive friction.
Deployable with named caveats. Context-dependent.
The score is a geometric mean — a single failed layer collapses it. Excellence in two cannot rescue a gap in the third. That is why hype scores low and proven, feasible, broadly-applicable work scores high. The restraint is the product.